AZ-NHIS’s dramatic conclusion on Tagrisso drug price negotiation
The AstraZeneca’s non-small cell lung cancer treatment Tagrisso(generic name: osimertinib), whose negotiation was broken down twice, finally passed the drug price negotiation.
The National Health Insurance Service(NHIS) and AstraZeneca Korea have dramatically concluded the 3rd drug price negotia...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
